Metabolic enzyme PFKFB4 activates transcriptional coactivator SRC-3 to drive breast cancer.
Nature, 2018/04;556(7700):249-254.
Dasgupta S[1, 2], Rajapakshe K[3], Zhu B[3], Nikolai BC[3], Yi P[3], Putluri N[3], Choi JM[3], Jung SY[4], Coarfa C[3], Westbrook TF[4], Zhang XH[3], Foulds CE[3, 5], Tsai SY[3], Tsai MJ[3], O'Malley BW[6]
Affiliations
PMID: 29615789DOI: 10.1038/s41586-018-0018-1
Impact factor: 69.504
Abstract
Alterations in both cell metabolism and transcriptional programs are hallmarks of cancer that sustain rapid proliferation and metastasis 1 . However, the mechanisms that control the interaction between metabolic reprogramming and transcriptional regulation remain unclear. Here we show that the metabolic enzyme 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 4 (PFKFB4) regulates transcriptional reprogramming by activating the oncogenic steroid receptor coactivator-3 (SRC-3). We used a kinome-wide RNA interference-based screening method to identify potential kinases that modulate the intrinsic SRC-3 transcriptional response. PFKFB4, a regulatory enzyme that synthesizes a potent stimulator of glycolysis 2 , is found to be a robust stimulator of SRC-3 that coregulates oestrogen receptor. PFKFB4 phosphorylates SRC-3 at serine 857 and enhances its transcriptional activity, whereas either suppression of PFKFB4 or ectopic expression of a phosphorylation-deficient Ser857Ala mutant SRC-3 abolishes the SRC-3-mediated transcriptional output. Functionally, PFKFB4-driven SRC-3 activation drives glucose flux towards the pentose phosphate pathway and enables purine synthesis by transcriptionally upregulating the expression of the enzyme transketolase. In addition, the two enzymes adenosine monophosphate deaminase-1 (AMPD1) and xanthine dehydrogenase (XDH), which are involved in purine metabolism, were identified as SRC-3 targets that may or may not be directly involved in purine synthesis. Mechanistically, phosphorylation of SRC-3 at Ser857 increases its interaction with the transcription factor ATF4 by stabilizing the recruitment of SRC-3 and ATF4 to target gene promoters. Ablation of SRC-3 or PFKFB4 suppresses breast tumour growth in mice and prevents metastasis to the lung from an orthotopic setting, as does Ser857Ala-mutant SRC-3. PFKFB4 and phosphorylated SRC-3 levels are increased and correlate in oestrogen receptor-positive tumours, whereas, in patients with the basal subtype, PFKFB4 and SRC-3 drive a common protein signature that correlates with the poor survival of patients with breast cancer. These findings suggest that the Warburg pathway enzyme PFKFB4 acts as a molecular fulcrum that couples sugar metabolism to transcriptional activation by stimulating SRC-3 to promote aggressive metastatic tumours.
MeSH terms
Activating Transcription Factor 4; Animals; Breast Neoplasms; Cell Line, Tumor; Female; Gene Expression Regulation, Neoplastic; Glucose; Glycolysis; Humans; Lung Neoplasms; Mice; Neoplasm Metastasis; Nuclear Receptor Coactivator 3; Pentose Phosphate Pathway; Phosphofructokinase-2; Phosphorylation; Phosphoserine; Prognosis; Purines; RNA Interference; Receptors, Estrogen; Transcriptional Activation; Transketolase; Xenograft Model Antitumor Assays
More resources
Full text:
Europe PubMed Central; PubMed Central
EndNote: Download